|Day Low/High||77.75 / 78.65|
|52 Wk Low/High||62.66 / 94.98|
This is because they would buy more of the winning stocks lower.
The uptick in the small- and mid-cap space bodes well for future capital appreciation.
The market is having a quiet day in front of the long holiday weekend. However, biotech is concluding another strong week, which makes two in a row. I'm noticing some small biotechs on the move today. Aratana Therapeutics (PETX) is up 7% today. Ther...
Keep cash on hand and be ready for oportunities as they arise.
AbbVie and Gilead Sciences are worth accumulating in a long and deep bear market for biotech.
We offer 10 names each in the Opportunistic Value portfolio and the Income-Oriented portfolio.
Home Depot shares were falling despite a strong first-quarter showing.
It is hard to see much growth in the market overall, until earnings growth returns.
After an asset price drop, large pharmaceutical companies are looking for strategic purchases.
Larry Robbins, Carson Block and John Khoury hold court at the 2106 Sohn Conference.
The interest areas of these investors span health care, hotels and international intrigue. Real Money takes a quick look at what they may discuss Wednesday.
The M&A activity is an incredible and a welcome sign.
This earnings season continues to disappoint, and technology names are leading the downward charge.
It's important to focus on hitting singles in this overbought and earnings-starved environment.
Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.
This will still be fourth quarter in a row that profits have declined year over year.
U.S. indices look to reverse yesterday's losses as crude prices continue their climb.
With low multiples and solid yields, these names look good for the long term.
ABBV is rising, and the current action could be the start of a strong move higher.
In this choppy market, the sweet spot is large-caps with these three core attributes.
I am starting to get more confident that the small caps are ready to bounce.
I like cheap smaller caps with little to no exposure to the global economy.
A breakdown below $52 should be the tipping point for further declines in ABBV.
If I had to guess, today's sharp rally was a function of monthly inflows, technical breakouts and programs. But it is only a guess. However, you will watch in the business media all the talking heads who liked yesterday's market and purchased opport...